🇺🇸 FDA
Pipeline program

Imsidolimab

ANB019-003

Phase 2 mab completed

Quick answer

Imsidolimab for Palmoplantar Pustulosis is a Phase 2 program (mab) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Palmoplantar Pustulosis
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials